Newsroom | 35572 results

PRINCETON, N.J.--(BUSINESS WIRE)--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollm...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollm...

中国北京--(BUSINESS WIRE)--(美国商业资讯)-- 百奥赛图（北京）医药科技股份有限公司（以下简称“百奥赛图”，HKEX：02315）欣然宣布，其合作伙伴IDEAYA Biosciences, Inc. (Nasdaq: IDYA)，一家专注于肿瘤精准治疗药物研发的公司，已获得美国食品药品监督管理局（FDA）的临床试验用新药（IND）批准，推进同类首创B7H3/PTK7双特异性抗体偶联物（ADC）项目的I期临床试验。IDEAYA预计将在2026年第一季度开始患者入组，初步评估B7H3和PTK7共表达的实体瘤类型，包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。 IDE034是一款潜在同类首创的双靶点B7H3/PTK7 TOP1 ADC，由百奥赛图自主开发，并于2024年7月授权给IDEAYA公司。此次IND获批标志着双方合作迈入重要里程碑，为推进IDE034后续的临床开发奠定基础，同时彰显了百奥赛图在双抗ADC发现与开发领域的技术实力。 百奥赛图董事长兼CEO沈月雷博士表示：“IDE034获批IND，是IDEAYA将首创TOP1 ADC管线拓展至双特异性、精准靶向策略的重要...

WASHINGTON--(BUSINESS WIRE)--The Public Access to Sunscreens (PASS) Coalition commends Congress for passing the SAFE Sunscreen Standards Act (H.R. 3686/S. 2491) as part of the recent reauthorization of the Over-the-Counter Monograph User Fee Act (OMUFA) in H.R. 5371. This action represents a pivotal step toward modernizing sunscreen ingredient approvals and expanding access to safe and innovative cancer prevention tools. For years, outdated regulatory frameworks have restricted Americans’ acces...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 1, 2025, the Compensation Committee of the company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 88,000 shares of common stock to four new employees under the Company’s 2024 Indu...

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and cur...

SAN FRANCISCO--(BUSINESS WIRE)--Salesforce (NYSE: CRM), the world’s #1 CRM, today announced that AstraZeneca (LSE/STO/Nasdaq: AZN), a global, science-led biopharmaceutical company, has selected Agentforce Life Sciences for Customer Engagement to help transform its customer engagement globally, fostering stronger relationships with healthcare professionals (HCPs) through data-driven, AI-powered engagement. This work will support AstraZeneca's commitment to push the boundaries of science to deliv...

WASHINGTON--(BUSINESS WIRE)--Dr. Krishnan Suthanthiran, President/Founder of TeamBest Global (TBG) companies and the International Society for Radiation Medicine & Molecular Imaging (ISRMMI), is urging closer collaboration with the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to accelerate the adoption of theranostics and broaden treatment options for cancer patients worldwide. TBG has long been recognized for developing cost-effective, innovative technologies, and advanced the...

BOSTON--(BUSINESS WIRE)--Foundation Medicine Achieves Historic Milestone of 100 Approved Companion Diagnostic Indications, Solidifying Leadership in Precision Medicine...